# A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia

> **NCT02954653** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 8 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **BIOLOGICAL:** PF-06747143
- **DRUG:** Cytarabine
- **DRUG:** Daunorubicin
- **DRUG:** Azacitidine
- **DRUG:** Decitabine

## Key facts

- **NCT ID:** NCT02954653
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-11-28
- **Primary completion:** 2017-12-05
- **Final completion:** 2017-12-05
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** The study was terminated due to a change in sponsor prioritization.
- **Last updated:** 2019-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02954653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02954653, "A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02954653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*